Accordingly, the overexpression of FKBP51 favours prostate cancer cell growth and impairs the effectiveness of antiandrogen therapies, for example, treatments with bicalutamide, that is frequently used in patients undergoing androgen ablation therapy [94]. This evidence concerns the gene FKBP4 and prostate cancer.